SGLT2 inhibitors |
Zinman et al, 20158
| Established CVD (100%)
| Oral empagliflozin 10 mg or 25 mg once daily vs placebo | Mean decrease of 0.24% vs placebo | Superiority:
| Superiority:
|
Neal et al, 20179
| Established CVD (66%)Risk factors for CVD (34%)†
| Oral canagliflozin 100 mg or 300 mg once daily vs placebo | Mean decrease of 0.58% vs placebo | Superiority:
| Non-significant:
|
Wiviott et al, 201910
| Established CVD (41%) Risk factors for CVD (59%)†
| Oral dapagliflozin 10 mg once daily vs placebo | Mean decrease of 0.42% vs placebo | Noninferior to placebo:
| Non-significant:
|
GLP1 agonists |
Marso et al, 201611
| Established CVD or CKD (81%)‡ Risk factors for CVD (19%)†
| SC liraglutide 1.8 mg once daily vs placebo | Mean decrease of 0.40% vs placebo | Superiority:
| Superiority:
|
Marso et al, 201612
| Established CVD orCKD (83%)‡ Risk factors for CVD (17%)†
| SC semaglutide 0.5 mg or 1.0 mg once weekly vs placebo | Mean HbA1c of 7.6% (0.5 mg) and 7.3% (1 mg) vs 8.3% (placebo) | Superiority:
| Non-significant:
|
Gerstein et al, 201913
| Established CVD (32%) Risk factors for CVD (68%)†
| SC dulaglutide 1.5 mg once weekly vs placebo | Mean decrease of 0.60% vs placebo | Superiority:
| Non-significant:
|